 |
|
|
| |
Evaluation of Drug-Drug Interaction Potential Between
Sofosbuvir/Velpatasvir and Atorvastatin
|
| |
| |
Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL
Rebecca Begley, Erik Mogalian, Brian McNabb, Gong Shen, Sherry Lee, John Ling, Anita Mathias
Gilead Sciences, Inc., Foster City, California, USA
References
1. Jacobson IM, et al. N Engl J Med 2013;368:1867-77; 2. Lawitz E, et al. N Engl J Med 2013;368:1878-87; 3. Lawitz E, et al. J Viral Hepat 2015;22:1011-9; 4. Curry M, et al.
N Engl J Med 2015;373:2618-28; 5. Feld J, et al. N Engl J Med 2015;373:2599-607; 6. Foster G, et al. N Engl J Med 2015;373:2608-17; 7. Lennernäs H. Clin Pharmacokinet
2003;42:1141-60; 8. Lipitor [package insert]. New York, NY: Pfizer Inc, 3/2015; 9. Juxtapid [package insert]. Cambridge, MA: Aegerion Pharmaceuticals, Inc., 5/2016;
10. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc., 2/2017; 11. Mogalian E, et al. CROI 2016, abstr 100.
|
| |
|
|
|
|
|
